The University of Nebraska Medical Center and Hemispherx Biopharma, Inc. are joining forces to take on pancreatic cancer, one of the most deadly forms of cancer. In mouse model studies, Hemispherx’s immune-enhancing drug, Ampligen—an immune-enhancer TLR3 agonist—will be administered with a peptide vaccine developed by UNMC. The study will test the capability of Ampligen to…